{
    "nctId": "NCT05486936",
    "briefTitle": "RapidPlan Models Establishment for Node-Positive Breast Cancer Treated With Hypofractionation Using Edge/Truebeam",
    "officialTitle": "RapidPlan Models Establishment for Node-Positive Breast Cancer Treated With Hypofractionation Using Edge/Truebeam",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 195,
    "primaryOutcomeMeasure": "\u2265Grade 2 acute radiation-induced toxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Aged 18-75 years old\n* Ipsilateral clinically diagnosed and histologically confirmed invasive breast cancer pT1-3\n* \u22651 pathologically positive axillary lymph nodes\n* Karnofsky Performance Status scoring \u226580\n* Surgery wound healed without infection\n* Anticipative overall survival \\>5 years\n* Pathologically surgical margin \\>2mm\n* ER (estrogen-receptor), PR (progesterone-receptor), HER2 (human epidermal growth factor receptor 2) and Ki67 testing can be performed on the primary breast tumor\n* Women of child-bearing potential must agree to use adequate contraception for up to 1 month before study treatment and the duration of study participation\n* Ability to understand and willingness to participate the research and sign the consent form\n\nExclusion Criteria:\n\n* Axillary dissection of less than 10 lymph nodes\n* Pathologically positive ipsilateral supraclavicular lymph node\n* Pathologically or radiologically confirmed positive ipsilateral internal mammary lymph nodes\n* Pregnant or lactating women\n* Treated with breast reconstruction surgery\n* Severe non-neoplastic medical comorbidities\n* History of non-breast malignancy within 5 years with the exception of lobular carcinoma in situ, basal cell carcinoma of the skin, carcinoma in situ of skin and carcinoma in situ of the cervix\n* simultaneous contralateral breast cancer\n* Previous RT to the neck, chest and/or ipsilateral axillary region\n* Active collagen vascular disease\n* Definitive pathological or radiologic evidence of distant metastatic disease\n* Primary T4 tumor\n* Interval between radical surgery (mastectomy or breast conserving surgery) and radiotherapy was more than 12 weeks or interval between last dose of adjuvant chemotherapy and radiotherapy was more than 8 weeks",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}